CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Monday reported a loss of $25.1 million in its third quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 28 cents.
The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 38 cents per share.
The genome editing company posted revenue of $7.5 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $1.6 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EDIT at https://www.zacks.com/ap/EDIT
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
